Regression was performed on chosen microarray information, with the slope and P value for the line of most effective match reported as well as the r2 value for the connection. All statistical analyses had been carried out with GraphPad Prism version six.00 (GraphPad Software program). Study approval. All patient samples were deidentified, plus the project was exempted by the Duke University Well being System Institutional Critique Board (protocol ID 00034541). All animal procedures were approved by the Duke University Institutional Animal Care and Use Committee (protocol A278-11-11).Acknowledgments We thank Michael Hogarty, the Children’s Oncology Group Neuroblastoma Biology Subcommittee, Wendy London, and Evan Plunkett for providing patient tissue and serum samples. We thank Linda Valentijn, Paul Yu, Harriett Stadt, Mary Hutson, Margaret Kirby, and Lisa Crose for providing reagents. We thank Lindsey Morgan and Terri Lucas for coordinating our animal facility use. We thank Julie Fuller for tissue processing. We’re grateful to Tam How, Catherine Gatza, Alison Meyer, Alisha Holtzhausen, Catherine Lavau, Rebekah Moehring, Jennifer Elderbroom, Rachel Hesler, and Jasmine Nee for technical help and Cheryl Alles for superior clerical assistance. We’re grateful to Daniel Wechsler, Dona Chikaraishi, Insulin Receptor web Christopher Kontos, and Julio Ramirez for invaluable mentoring all through this project. This function was supported in portion by NIH grants F30 CA168043-01 (to E.H. Knelson), R01-CA136786 (to G.C. Blobe), and R01-CA135006 (to G.C. Blobe). Received for publication March 1, 2013, and accepted in revised form August eight, 2013. Address correspondence to: Gerard C. Blobe, Duke University Medical Center, Box 91004, Durham, North Carolina 27708, USA. Phone: 919.668.1359; Fax: 919.681.6906; E-mail: [email protected] 123 Number 11 Novemberhttp://jci.orgresearch article1. National Cancer Institute. Surveillance, Epidemiology and End Benefits (SEER) Database. NIH Web site. http://seer.cancer.gov/. Accessed August 30, 2013. 2. Mullassery D, Dominici C, Jesudason EC, McDowell HP, Losty PD. Neuroblastoma: modern management. Arch Dis Kid Educ Pract Ed. 2009;94(six):17785. three. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106120. four. De Bernardi B, et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol. 2008; 26(ten):1710716. 5. Retrosi G, et al. Morbidity following ganglioneuroma excision: is surgery needed Eur J Pediatr Surg. 2011;21(1):337. six. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene. 2010;29(11):1566579. 7. Maris JM. Current advances in neuroblastoma. N Engl J Med. 2010;362(23):2202211. 8. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; three(3):20316. 9. Seeger RC, et al. Association of many copies in the N-myc oncogene with fast progression of neuroblastomas. N Engl J Med. 1985; 313(18):Nav1.3 site 1111116. ten. Schwab M, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and also a neuroblastoma tumour. Nature. 1983;305(5931):24548. 11. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 2011;21(4):25666. 12. Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA. MYCN oncoprotein targets and their therapeutic possible. Cancer Lett. 2010;293(2):14457. 13. Matthay KK, et al. Long-term outcomes for ch.
